Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

By Deena Beasley (Reuters) -People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

UnitedHealth Group’s ( UNH) new CEO, Stephen Hemsley, is shaking up the senior management of the company, appointing Patrick Conway, newly named CEO of the managed care giant’s Optum unit, as the head ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.